DK2062023T4 - Intergeniske sites mellem konserverede gener i genomet af modificeret vaccinia ankara (mva)-vacciniavirus - Google Patents

Intergeniske sites mellem konserverede gener i genomet af modificeret vaccinia ankara (mva)-vacciniavirus Download PDF

Info

Publication number
DK2062023T4
DK2062023T4 DK07874019.8T DK07874019T DK2062023T4 DK 2062023 T4 DK2062023 T4 DK 2062023T4 DK 07874019 T DK07874019 T DK 07874019T DK 2062023 T4 DK2062023 T4 DK 2062023T4
Authority
DK
Denmark
Prior art keywords
mva
genome
sequence
hiv
dna sequence
Prior art date
Application number
DK07874019.8T
Other languages
English (en)
Other versions
DK2062023T3 (da
Inventor
Bernard Moss
Linda Wyatt
Patricia Earl
Original Assignee
The Government Of The Us Secretary Dept Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2062023(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Government Of The Us Secretary Dept Of Health And Human Services filed Critical The Government Of The Us Secretary Dept Of Health And Human Services
Application granted granted Critical
Publication of DK2062023T3 publication Critical patent/DK2062023T3/da
Publication of DK2062023T4 publication Critical patent/DK2062023T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8636—Vaccina virus vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (17)

1. Rekombinant modificeret Vaccinia Ankara (MVA)-virus omfattende en heterolog DNA-sekvens indsat i en intergenisk region (IGR) af MVA-genomet, der er anbragt mellem, eller flankeret af, de åbne læserammer (ORFs) 069-070 af MVA-genomet i nomenklaturet af CDC/Acambis.
2. MVA ifølge krav 1, hvor den heterologe DNA-sekvens omfatter mindst én kodende sekvens, under den transkriptionelle kontrol af et poxvirus-transkriptionskontrolelement.
3. MVA ifølge et hvilket som helst af kravene 1-2, hvor den heterologe DNA-sekvens koder for ét eller flere proteiner, polypeptider eller peptider.
4. MVA ifølge et hvilket som helst af kravene 1-3, hvor den heterologe DNA-sekvens er afledt af human immunodeficient virus (HIV).
5. MVA ifølge krav 4, hvor den heterologe DNA-sekvens afledt fra human immunodeficient virus koder for HIV env.
6. MVA ifølge et hvilket som helst af kravene 1-5, hvor MVA -genomet er det fra MVA deponeret under ATCC under adgangsnummer PTA-5095.
7. MVA ifølge et hvilket som helst af kravene 1 til 5, hvor MVA -genomet er det som har sekvensen fra Genbank adgangsnummer AY603355.
8. MVA ifølge et hvilket som helst af kravene 1 til 5, hvor MVA -genomet er det som har sekvensen fra Genbank adgangsnummer U94848.
9. Plasmidvektor omfattende en DNA-sekvens afledt fra eller homolog med genomet fra en MVA, hvor DNA-sekvensen omfatter i) et komplet eller delvis fragment fra en IGR-sekvens anbragt mellem komplette sekvenser fra ORF's 069-070 i nomenklaturet af CDC/Acambis fra MVA-genomet og ii) indsat i IGR-sekvensen et kloningssted til indsætningen afen DNA-sekvens der er heterolog til genomet af MVA; og iii) eventuelt, en reporter- eller selektions-gen-kassette.
10. Plasmidvektor omfattende en DNA-sekvens afledt af eller homolog til genomet fra en MVA, hvor DNA-sekvensen omfatter i) komplette sekvenser fra ORF's 069-070 i nomenklaturet af CDC/Acambis og ii) indsat mellem disse ORF's, et kloningssted til indsætningen af en DNA-sekvens der er heterolog til genomet fra MVA; og iii) eventuelt en reporter- eller selektions-gen-kassette.
11. Plasmidvektoren ifølge et hvilket som helst af kravene 9 til 10, hvor DNA-sekvensen er afledt fra eller homolog til genomet fra MVA deponeret under ATCC under deponeringsnummer PTA-5095.
12. Plasmidvektoren ifølge et hvilket som helst af kravene 9 til 10, hvor DNA-sekvensen er afledt fra eller homolog til genomet fra MVA med sekvensen fra Genbank adgangsnummer AY603355.
13. Plasmidvektoren ifølge et hvilket som helst af kravene 9 til 10, hvor DNA-sekvensen er afledt fra eller homolog til genomet fra MVA med sekvensen fra Genbank adgangsnummer U94848.
14. Farmaceutika, vaccine eller immunogen sammensætning omfattende MVA ifølge et hvilket som helst af kravene 1 til 8.
15. MVA ifølge et hvilket som helst af kravene 1 til 8 til anvendelse som medikament, immunogen sammensætning eller vaccine.
16. Anvendelse af MVA ifølge et hvilket som helst af kravene 1 til 8 til fremstillingen af et medikament, immunogen sammensætning, eller vaccine til behandlingen eller profylakse af en virusinfektion eller en prolifererende sygdom.
17. MVA ifølge et hvilket som helst af kravene 1-8 til anvendelse i behandling eller profylakse af en virusinfektion eller en prolifererende sygdom.
DK07874019.8T 2006-08-25 2007-08-24 Intergeniske sites mellem konserverede gener i genomet af modificeret vaccinia ankara (mva)-vacciniavirus DK2062023T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84009306P 2006-08-25 2006-08-25
US84075506P 2006-08-28 2006-08-28
PCT/IB2007/004575 WO2008142479A2 (en) 2006-08-25 2007-08-24 Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus

Publications (2)

Publication Number Publication Date
DK2062023T3 DK2062023T3 (da) 2012-12-17
DK2062023T4 true DK2062023T4 (da) 2017-02-20

Family

ID=40032225

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07874019.8T DK2062023T4 (da) 2006-08-25 2007-08-24 Intergeniske sites mellem konserverede gener i genomet af modificeret vaccinia ankara (mva)-vacciniavirus
DK11183527.8T DK2402451T3 (da) 2006-08-25 2007-08-24 Fremgangsmåde til stabilisering af et DNA-insert i en rekombinant vacciniavektor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11183527.8T DK2402451T3 (da) 2006-08-25 2007-08-24 Fremgangsmåde til stabilisering af et DNA-insert i en rekombinant vacciniavektor

Country Status (6)

Country Link
US (3) US9133478B2 (da)
EP (2) EP2062023B2 (da)
CN (3) CN106148288A (da)
DK (2) DK2062023T4 (da)
ES (1) ES2396376T5 (da)
WO (1) WO2008142479A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106148288A (zh) 2006-08-25 2016-11-23 美国国有健康与人类服务部(马里兰州) 重组修饰的安卡拉痘苗病毒及其应用、质粒载体及其应用
BRPI0809600B1 (pt) 2007-03-30 2023-01-24 The Research Foundation Of State University Of New York Vírus atenuado útil para vacinas
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
CA2777744C (en) 2009-10-16 2019-09-24 Bernard Moss Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
AU2013293570B2 (en) 2012-07-27 2019-05-23 City Of Hope An MVA vaccine for delivery of a UL128 complex and preventing CMV infection
DK3198017T3 (da) 2014-09-26 2021-04-12 Us Health Virusbaserede ekspressionsvektorer og anvendelser deraf
US11701418B2 (en) * 2015-01-12 2023-07-18 Geovax, Inc. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
WO2017059122A1 (en) 2015-09-29 2017-04-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of treating and preventing amyotrophic lateral sclerosis
AU2017206102C1 (en) 2016-01-08 2022-02-10 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
WO2017136419A1 (en) 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
WO2018064516A1 (en) * 2016-09-30 2018-04-05 Monsanto Technology Llc Method for selecting target sites for site-specific genome modification in plants
WO2018153460A1 (en) * 2017-02-23 2018-08-30 Probiogen Ag Novel vaccinia virus vectors related to mva with extensive genomic symmetries
US20200171141A1 (en) * 2017-07-18 2020-06-04 Geovax, Inc. Compositions and Methods for Generating an Immune Response to LASV
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
JP2021535730A (ja) * 2018-05-11 2021-12-23 シティ・オブ・ホープCity of Hope 複数の部位メガロウイルス（ｃｍｖ）抗原の発現のためのｍｖａベクター及びその使用
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
CN111063391B (zh) * 2019-12-20 2023-04-25 海南大学 一种基于生成式对抗网络原理的不可培养微生物筛选系统
EP4247410A1 (en) * 2020-11-19 2023-09-27 KaliVir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
IL308018A (en) 2021-04-30 2023-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for different MHC expression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003219057A1 (en) † 2002-03-15 2003-09-29 Baxter Healthcare S.A. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
JP4895505B2 (ja) * 2002-05-16 2012-03-14 バヴァリアン・ノルディック・アクティーゼルスカブ 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域
AU2004291024B2 (en) † 2003-02-20 2009-09-17 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Novel insertion sites in pox vectors
WO2004098534A2 (en) † 2003-02-24 2004-11-18 Therion Biologics Corporation Methods for delivering angiogenic modulators using pox viruses
EP2359851A3 (en) * 2003-03-28 2011-08-31 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
DK1694364T3 (da) † 2003-11-12 2014-07-21 Us Government System til behandling og forebyggelse af brystcancer
CN106148288A (zh) 2006-08-25 2016-11-23 美国国有健康与人类服务部(马里兰州) 重组修饰的安卡拉痘苗病毒及其应用、质粒载体及其应用
EP2199400A1 (en) 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH Single recombination system and methods of use
CA2777744C (en) * 2009-10-16 2019-09-24 Bernard Moss Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites

Also Published As

Publication number Publication date
CN106148288A (zh) 2016-11-23
EP2402451B1 (en) 2018-03-21
EP2062023A2 (en) 2009-05-27
EP2402451A3 (en) 2012-04-18
EP2062023B1 (en) 2012-10-03
CN103255110A (zh) 2013-08-21
US20160040188A1 (en) 2016-02-11
CN101563463B (zh) 2013-03-27
EP2402451A2 (en) 2012-01-04
DK2402451T3 (da) 2018-06-25
CN103255110B (zh) 2016-04-20
CN101563463A (zh) 2009-10-21
US10421978B2 (en) 2019-09-24
US9133478B2 (en) 2015-09-15
ES2396376T3 (es) 2013-02-21
WO2008142479A2 (en) 2008-11-27
DK2062023T3 (da) 2012-12-17
US20200071724A1 (en) 2020-03-05
ES2396376T5 (es) 2017-05-31
US20100143402A1 (en) 2010-06-10
EP2062023B2 (en) 2016-11-09
WO2008142479A3 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
US20200071724A1 (en) Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus
US9879231B2 (en) Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites
US8916172B2 (en) MVA expressing modified HIV envelope, gag, and pol genes
JP5178196B2 (ja) クレードＡ／Ｇ、クレードＢ、およびクレードＣ改変ＨＩＶｅｎｖ、ｇａｇ、およびｐｏｌ遺伝子を発現する組換えＭＶＡウイルス
AU2004226345B2 (en) MVA virus expressing modified HIV envelope, gag, and pol genes
AU2002252199A1 (en) MVA expressing modified HIV envelope, GAG, and POL genes
AU2012202786B8 (en) Recombinant MVA viruses expressing Clade A/G, Clade B, and Clade C modified HIV ENV, GAG and POL genes